{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:15:36Z","timestamp":1784297736717,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.cllc.2022.09.010","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T14:22:01Z","timestamp":1665670921000},"page":"e39-e49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Real-world ALK Testing Trends in Patients With Advanced Non\u2013Small-Cell Lung Cancer in the United States"],"prefix":"10.1016","volume":"24","author":[{"given":"Huamao M.","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifeng","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen A.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Lovly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Humphries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2022.09.010_bib0001","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2022.09.010_bib0002","article-title":"Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis","volume":"9","author":"Fan","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cllc.2022.09.010_bib0003","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1158\/1078-0432.CCR-13-0318","article-title":"ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non\u2013small cell lung cancer","volume":"19","author":"Gainor","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2022.09.010_bib0004","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"ALEX Trial Investigators. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.09.010_bib0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2022.09.010_bib0006","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.09.010_bib0007","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2022.09.010_bib0008","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.cllc.2022.09.010_bib0009","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.09.010_bib0010","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.cllc.2022.09.010_bib0011","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Guideline Name V.X.20XX. \u00a9 National Comprehensive Cancer Network, Inc. 20XX. All rights reserved. Accessed [Month and Day, Year]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"10.1016\/j.cllc.2022.09.010_bib0012","first-page":"1","article-title":"Advancements in next-generation sequencing for diagnosis and treatment of non-small-cell lung cancer","volume":"3","author":"Lu","year":"2017","journal-title":"Chronic Dis Transl Med"},{"key":"10.1016\/j.cllc.2022.09.010_bib0013","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1634\/theoncologist.2017-0078","article-title":"FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond","volume":"22","author":"Pai-Scherf","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2022.09.010_bib0014","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1634\/theoncologist.2015-0507","article-title":"FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy","volume":"21","author":"Kazandjian","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2022.09.010_bib0015","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1158\/1078-0432.CCR-17-0540","article-title":"U.S. Food and Drug Administration approval summary: atezolizumab for metastatic non-small cell lung cancer","volume":"23","author":"Weinstock","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2022.09.010_bib0016","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cllc.2020.08.003","article-title":"Immunotherapy treatment patterns and outcomes among ALK-with non\u2013small-cell lung cancer","volume":"22","author":"Jahanzeb","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2022.09.010_bib0017","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2022.09.010_bib0018","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2022.09.010_bib0019","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/EDBK_280795","article-title":"Checkpoint blockade in lung cancer with driver mutation: choose the road wisely","volume":"40","author":"Calles","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.cllc.2022.09.010_bib0020","article-title":"Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR","author":"Ma","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cllc.2022.09.010_bib0021","unstructured":"Birnbaum B, Nussbaum N, Seidl-Rathkopf K, et\u00a0al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. 2020;arXiv:2001.09765v1."},{"key":"10.1016\/j.cllc.2022.09.010_bib0022","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41586-021-03430-5","article-title":"Evaluating eligibility criteria of oncology trials using real-world data and AI","volume":"592","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cllc.2022.09.010_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00159","article-title":"ALK testing trends and patterns among community practices in the United States","volume":"2","author":"Illei","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2022.09.010_bib0024","doi-asserted-by":"crossref","first-page":"e1050","DOI":"10.1002\/onco.13779","article-title":"Adherence to National Comprehensive Cancer Network ALK testing guidelines for patients with advanced non-small cell lung cancer in U.S. Community Medical Centers","volume":"26","author":"Bernicker","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2022.09.010_bib0025","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.canep.2015.04.005","article-title":"ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer","volume":"39","author":"Gu\u00e9rin","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.cllc.2022.09.010_bib0026","doi-asserted-by":"crossref","first-page":"e901","DOI":"10.1016\/j.cllc.2021.05.006","article-title":"Understanding contemporary molecular biomarker testing rates and trends for metastatic NSCLC among community oncologists","volume":"22","author":"Waterhouse","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2022.09.010_bib0027","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s12325-020-01617-2","article-title":"Clinical impact of adherence to NCCN guidelines for biomarker testing and first-line treatment in advanced non-small cell lung cancer (aNSCLC) using real-world electronic health record data","volume":"38","author":"John","year":"2021","journal-title":"Adv Ther"},{"issue":"8","key":"10.1016\/j.cllc.2022.09.010_bib0028","doi-asserted-by":"crossref","first-page":"975","DOI":"10.5858\/arpa.2021-0029-OA","article-title":"Understanding factors associated with anaplastic lymphoma kinase testing delays in patients with non-small cell lung cancer in a large real-world oncology database","volume":"146","author":"Bernicker","year":"2022","journal-title":"Arch Pathol Lab Med"},{"issue":"12","key":"10.1016\/j.cllc.2022.09.010_bib0029","doi-asserted-by":"crossref","first-page":"971","DOI":"10.4236\/jct.2019.1012083","article-title":"Biomarker testing rates in patients with advanced non-small cell lung cancer treated in the community","volume":"10","author":"Nadler","year":"2019","journal-title":"J Cancer Ther"},{"key":"10.1016\/j.cllc.2022.09.010_bib0030","doi-asserted-by":"crossref","first-page":"570","DOI":"10.21037\/tlcr.2017.07.06","article-title":"Immunohistochemistry for predictive biomarkers in non-small cell lung cancer","volume":"6","author":"Mino-Kenudson","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2022.09.010_bib0031","first-page":"70","article-title":"Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements","volume":"3","author":"Teixid\u00f3","year":"2014","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2022.09.010_bib0032","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13046-017-0591-4","article-title":"High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods","volume":"36","author":"Su","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.cllc.2022.09.010_bib0033","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/JTO.0b013e318290868f","volume":"8","author":"Lindeman","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.09.010_bib0034","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/annonc\/mdv208","article-title":"Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer","volume":"26","author":"Lim","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2022.09.010_bib0035","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.lungcan.2020.03.005","article-title":"Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer","volume":"143","author":"Sheinson","year":"2020","journal-title":"Lung Cancer"},{"issue":"8_suppl","key":"10.1016\/j.cllc.2022.09.010_bib0036","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.8_suppl.212","article-title":"Real-world concordance of clinical practice with ASCO and NCCN guidelines for EGFR\/ALK testing in aNSCLC","volume":"35","author":"Ruggiero","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.09.010_bib0037","unstructured":"OPDIVO (nivolumab) Injection [prescribing information]: Princeton, NJ: Bristol-Myers Squibb; 2022. Accessed July 30, 2022."},{"key":"10.1016\/j.cllc.2022.09.010_bib0038","unstructured":"TECENTRIQ (atezolizumab) Injection [prescribing information]: San Francisco, CA: Genentech Inc; 2022. Accessed July 30, 2022."},{"key":"10.1016\/j.cllc.2022.09.010_bib0039","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jtho.2018.09.001","article-title":"Increased hepatotoxicity associated with sequential immune checkpoint inhibitor and crizotinib therapy in patients with non-small cell lung cancer","volume":"14","author":"Lin","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.09.010_bib0040","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jtho.2018.02.022","article-title":"Phase 1\/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation\u2014positive advanced nonesmall cell lung cancer (CheckMate 370)","volume":"13","author":"Spigel","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.09.010_bib0041","doi-asserted-by":"crossref","unstructured":"Felip E, De Braud FG, Maur M, et\u00a0al. Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK\u00fe) advanced nonesmall cell lung cancer (NSCLC), Abstract Presented at: American Society of Clinical Oncology Annual Meeting June 2-6, 2017, Chicago, IL.","DOI":"10.1200\/JCO.2017.35.15_suppl.2502"},{"key":"10.1016\/j.cllc.2022.09.010_bib0042","first-page":"15s","article-title":"Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC)","volume":"36","author":"Kim","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.09.010_bib0043","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1084\/jem.20161462","article-title":"What does PD-L1 positive or negative mean?","volume":"213","author":"Ribas","year":"2016","journal-title":"J Exp Med"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422002133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422002133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:14:01Z","timestamp":1761506041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730422002133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1525730422002133"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2022.09.010","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world ALK Testing Trends in Patients With Advanced Non\u2013Small-Cell Lung Cancer in the United States","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2022.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}